Defeng Kong

Dr. Defeng Kong


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YWYaoyao Wang
Yaoyao Wang
XCXianzhen Chen
Xianzhen Chen
YWYongdong Wang
Yongdong Wang
YYYunxian Yu
Yunxian Yu
BZBoya Zhang
Boya Zhang
HCHao Cheng
Hao Cheng
Background/Objectives: Elderly patients (≥65 years) with atopic dermatitis (AD) often carry multimorbidity and face elevated risks with Janus kinase (JAK) inhibitors. Phase III trials included few older adults, and real-world data beyond 12 months remain scarce. We evaluated 36-month efficacy, safety, and drug persistence of upadacitinib 15 mg once daily in 62 Chinese elderly patients. Methods: This retrospective cohort study was conducted at Sir Run Run Shaw Hospital (March 2022-July 2026). All patients received upadacitinib 15 mg once daily. Assessments included Week 4 pruritus Numerical Rating Scale (NRS) response, Eczema Area and Severity Index (EASI) 75/90, and Investigator’s Global Assessment (IGA) 0/1 at Weeks 12 and 24. Drug persistence was estimated with the Kaplan–Meier method (36-month cutoff), and predictors were identified by Cox regression. Results: Median age was 70.0 years, 75.8% were male, and baseline EASI was 34.5, with substantial comorbidity (Charlson Comorbidity Index [CCI] 5.0; psychotropic use 46.8%). Week 4 itch response was 70.8%. EASI 75 reached 75.0% (IGA 0/1 44.4%) at Week 12, rising to 88.0% (64.0%) at Week 24. Persistence declined from 88.7% at Month 3 to 66.1% at Month 6, the steepest drop, reaching 38.7% at Month 36. Treatment-emergent adverse events (TEAEs) occurred in 54.8% and serious adverse events (SAEs) in 8.1%, with herpesvirus infection (21.0%) being the most common event, and there were no adverse event (AE)-related discontinuations, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE). In multivariate analysis, Week 4 itch response predicted longer persistence (hazard ratio [HR] = 0.203, 95% confidence interval [CI]: 0.091-0.452, p < 0.001), while psychotropic medication use predicted shorter persistence (HR = 2.814, 95% CI: 1.237-6.403, p = 0.014). Conclusions: Upadacitinib showed robust efficacy and acceptable safety over 36 months in elderly AD patients. Persistence dropped most sharply between Months 3 and 6. Week 4 itch response and psychotropic medication use independently predicted persistence. A structured Month 3 visit integrating itch reassessment, mental health screening, and dose optimization may improve long-term outcomes.

29 May 2025 in Eurasian Journal of Medicine and Oncology
Verified
Journal Article
Open access
PDF file
XJXiaoyun Jiang
Xiaoyun Jiang
DKDefeng Kong
Defeng Kong
HCHao Cheng
Hao Cheng
Introduction: Research on the impact of ultraviolet (UV)-related genes on the prognosis of melanoma is rare. Objective: This study aimed to explore the role of UV-associated genes in skin melanoma and their impact on prognosis. Methods: We evaluated the prognostic implications of UV-associated genes in cutaneous melanoma and developed a predictive model for patient outcomes utilizing skin melanoma datasets sourced from The Cancer Genome Atlas. Subsequently, we investigated the correlation between UV-associated genes and the local immune environment within cutaneous melanoma. Results: The developed prognostic model for cutaneous melanoma holds significant value for clinicians in assessing patient outcomes. The expression levels of UV-associated genes appear to influence the infiltration degree of various immune cells within the tumor microenvironment, including T cells and M1 macrophages. In addition, the model was able to predict melanoma prognosis and stratify melanoma patients, with patients in the high-risk group having a worse prognosis. Results also indicated that the high-risk group exhibited reduced infiltration of cytotoxic immune cells in the tumor tissue than the low-risk group. Conclusion: The findings from this novel study have the potential to identify new therapeutic targets in treating cutaneous melanoma.